Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
复制标题
单倍体相同的 CD19 嵌合抗原受体 T 细胞和干细胞的共同输注在难治性急性淋巴细胞白血病中实现了供体完全植入
DOI：
10.1186/s13045-016-0357-z
复制
发表时间：
2016-11-25
影响因子：
28.5
通讯作者：
Ai H
中科院分区：
文献类型：
--
作者：
Cai B;Guo M;Wang Y;Zhang Y;Yang J;Guo Y;Dai H;Yu C;Sun Q;Qiao J;Hu K;Zuo H;Dong Z;Zhang Z;Feng M;Li B;Sun Y;Liu T;Liu Z;Wang Y;Huang Y;Yao B;Han W;Ai H
研究背景老年复发难治性急性淋巴细胞白血病（ALL）患者预后较差。自体 CD19 嵌合抗原受体修饰 T (CAR-T) 细胞有潜力治愈 B 细胞 ALL 患者；然而，同种异体 CD19 CAR-T 细胞的安全性和有效性仍待确定。 病例介绍我们治疗了一名 71 岁的复发难治性 ALL 女性患者，她在诱导化疗后接受了单倍体相同供体来源的 CD19 定向 CAR-T 细胞和动员外周血干细胞 (PBSC) 的共同输注。通过流式细胞术实现了无法检测到的微小残留病，并建立了完整的供体细胞移植。检测到细胞因子的短暂释放和轻度发烧。第 14 天至第 18 天观察到血清乳酸脱氢酶、丙氨酸转氨酶、胆红素和谷草转氨酶显着升高，所有这些在免疫抑制治疗后都是可逆的。结论我们的初步结果表明，单倍体一致供体来源的 CAR-T 细胞和动员的 PBSC 的共同输注可能会诱导复发和难治性 ALL 中的完全供体植入包括老年患者，但仍应警惕与供体细胞输注相关的并发症。试验注册异基因CART-19治疗老年复发/难治性CD19+ ALL。 NCT02799550
BackgroundElderly patients with relapsed and refractory acute lymphoblastic leukemia (ALL) have poor prognosis. Autologous CD19 chimeric antigen receptor-modified T (CAR-T) cells have potentials to cure patients with B cell ALL; however, safety and efficacy of allogeneic CD19 CAR-T cells are still undetermined.Case presentationWe treated a 71-year-old female with relapsed and refractory ALL who received co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized peripheral blood stem cells (PBSC) following induction chemotherapy. Undetectable minimal residual disease by flow cytometry was achieved, and full donor cell engraftment was established. The transient release of cytokines and mild fever were detected. Significantly elevated serum lactate dehydrogenase, alanine transaminase, bilirubin and glutamic-oxalacetic transaminase were observed from days 14 to 18, all of which were reversible after immunosuppressive therapy.ConclusionsOur preliminary results suggest that co-infusion of haplo-identical donor-derived CAR-T cells and mobilized PBSCs may induce full donor engraftment in relapsed and refractory ALL including elderly patients, but complications related to donor cell infusions should still be cautioned.Trial registrationAllogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL. NCT02799550
登录
查看更多内容
影响因子：
20.3
作者：
Przepiorka, D;Kernan, NA;Light, S
通讯作者：
Light, S
输注HLA不匹配的外周血干细胞可改善老年急性髓系白血病患者的化疗效果
影响因子：
20.3
作者：
Guo, Mei;Hu, Kai-Xun;Ai, Hui-Sheng
通讯作者：
Ai, Hui-Sheng
表达 CD19 嵌合抗原受体的自体或供体来源的 T 细胞在患有髓外白血病的成人 B-ALL 中的耐受性和疗效。
影响因子：
7.2
作者：
Dai H;Zhang W;Li X;Han Q;Guo Y;Zhang Y;Wang Y;Wang C;Shi F;Zhang Y;Chen M;Feng K;Wang Q;Zhu H;Fu X;Li S;Han W
通讯作者：
Han W
DOI：
10.1056/nejmoa1407222
发表时间：
2014-10-16
期刊：
The New England journal of medicine
影响因子：
--
作者：
Maude SL;Frey N;Shaw PA;Aplenc R;Barrett DM;Bunin NJ;Chew A;Gonzalez VE;Zheng Z;Lacey SF;Mahnke YD;Melenhorst JJ;Rheingold SR;Shen A;Teachey DT;Levine BL;June CH;Porter DL;Grupp SA
通讯作者：
Grupp SA
影响因子：
2.6
作者：
Chen, HR;Ji, SQ;Xun, CQ
通讯作者：
Xun, CQ